Ortin Laboratories Ltd
NSE:ORTINLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 5-Year Average (1.8), the stock would be worth ₹-18.61 (195% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.9 | ₹19.63 |
0%
|
| 5-Year Average | 1.8 | ₹-18.61 |
-195%
|
| Industry Average | 57.9 | ₹-587.66 |
-3 094%
|
| Country Average | 49.7 | ₹-504.7 |
-2 671%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
O
|
Ortin Laboratories Ltd
NSE:ORTINLAB
|
159.6m INR | -1.9 | -2.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 27.4 |
| Median | 49.7 |
| 70th Percentile | 92 |
| Max | 57 010.1 |
Other Multiples
Ortin Laboratories Ltd
Glance View
Ortin Laboratories Ltd. engages in the manufacture of drug intermediates and pharmaceuticals products. The company is headquartered in Hyderabad, Telangana. The company manufactures a range of pharmaceutical formulations of tablets, capsules, syrups and dry powders. The firm's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. The company is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.
